
1. j viral hepat. 2019 aug;26(8):1019-1026. doi: 10.1111/jvh.13114. epub 2019 jun 2.

off-therapy precipitous hbsag decline predicts hbsag loss finite entecavir 
therapy hbeag-negative patients.

jeng wj(1)(2)(3), chang ml(1)(2)(3), liaw yf(1)(2).

author information: 
(1)liver research unit, chang gung memorial hospital, taoyuan, taiwan.
(2)college medicine, chang gung university, taoyuan, taiwan.
(3)department gastroenterology hepatology, chang gung memorial hospital,
taoyuan, taiwan.

cessation nucleos(t)ide analogue (nuc) therapy hbeag-negative patients may 
increase hbsag loss rate patients sustained remission (sr) and
non-retreated clinical relapsers (cr). investigate compare hbsag
kinetics end treatment (eot) hbsag loss patients, serial
serum samples eot 36 sr 12 cr hbsag loss (study group) an
1:1 matched control remained hbsag-seropositive (control group) assayed 
retrospectively quantitative hbsag (qhbsag). results showed study
group sr cr comparable eot features except sr lower eot qhbsag (67.5 
vs 350.5 iu/ml; p = 0.02; < 100 iu/ml: 58.3% vs 25%; p = 0.09). showed
gradual qhbsag decrease "precipitous hbsag decline" (>0.5 log10 iu/ml in
1 year) prior hbsag loss. patients eot qhbsag <100 showed earlier
(<12 months) "precipitous hbsag decline" (91.7% vs 58.3%; p = 0.017) sooner
hbsag loss (5.5 vs 21.9 months; p = 0.026). control group also showed gradual
qhbsag decrease less frequent "precipitous hbsag decline" (39.6% vs 100%;
p < 0.001) occurred later (15.1 vs 5.7 months; p = 0.003) less
steep (slope -0.6 vs -1.65 log10 iu/ml/year; p < 0.001). hbsag loss achieved 
in 92.9% patients "precipitous hbsag decline" >0.76 log10 iu/ml in
1 year. conclusion, sr cr groups showed gradual hbsag decrease
followed "precipitous hbsag decline", prerequisite hbsag
loss. lower eot hbsag sr group qhbsag <100 iu/ml may reflect better
immune control hence followed sooner hbsag loss.

© 2019 john wiley & sons ltd.

doi: 10.1111/jvh.13114 
pmid: 31009126  [indexed medline]

